Northwest Biotherapeutics (NWBO) Profit After Tax (2010 - 2026)

Northwest Biotherapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$2.9 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 86.34% year-over-year to -$2.9 million in Q1 2026; TTM through Mar 2026 was -$47.5 million, a 45.13% increase from a year earlier, with the FY2025 full-year figure at -$60.2 million, up 28.11% from the prior year.
• Profit After Tax fell to -$2.9 million in Q1 2026 per NWBO's latest filing, from $1.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at $1.4 million in Q4 2025 and bottomed at -$32.9 million in Q3 2022.
• The 5-year median for Profit After Tax is -$19.2 million (2025), against an average of -$19.0 million.
• Across the five-year window, Profit After Tax plunged 772.74% in 2022 and jumped 104.93% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$28.3 million in 2022, then soared by 38.65% to -$17.4 million in 2023, then sank by 62.04% to -$28.1 million in 2024, then soared by 104.93% to $1.4 million in 2025, then slumped by 309.22% to -$2.9 million in 2026.
• Per Business Quant, the three latest NWBO Profit After Tax figures stand at -$2.9 million (Q1 2026), $1.4 million (Q4 2025), and -$26.8 million (Q3 2025).